HYMOVIS High Molecular Weight Viscoelastic Hyaluronan
PMA P150010
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP150010 | Date28 Aug 2015 | StatusActive |
Official records
- FDA PMA database P150010
From the FDA record
FDA PMA P150010
- Received by the FDA
- 25 Feb 2015
- FDA decision
- 28 Aug 2015
- FDA review time
- 184 days from receipt to decision
- Docket number
- 15M-3256
APPROVAL FOR HYMOVIS. THIS DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Trade name
- Hymovis
- Generic name
- Acid, hyaluronic, intraarticular
- PMA number
- FDA product code
- MOZ
- Device class
- Class III
- Advisory committee
- Orthopedic
- FDA decision
- APPR Approved
Overview
AI-generated summary, 18 Sep 2026
Hymovis is an intraarticular acid hyaluronic device classified as a Class III medical product. It is formulated as a high molecular weight viscoelastic hyaluronan designed to restore synovial fluid properties in osteoarthritic joints, providing lubrication and cushioning to alleviate joint pain and improve mobility.
The device is supplied as a sterile, single-use injectable solution intended for intraarticular administration in patients with knee osteoarthritis unresponsive to conservative therapies. It is regulated under FDA PMA approval (P150010) and distributed in pre-filled syringes, requiring refrigeration prior to use. Compliance with FDA guidelines ensures its safety and efficacy for intraarticular use, with no MRI safety restrictions specified.
Devices cleared under P150010
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe 89122-0496-63 | 89122-0496-63 / 89122-0496-63 | M71389122049663A16 | Total Volume 3 mL | No longer on the market |
| Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe 89122-4966-30 | 89122-4966-30 / 89122-4966-30 | M71389122496630A16 | Total Volume 3 mL | No longer on the market |
| Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe FID185704 | FID185704 / FID185704 | M71389122496630SAM1 | Total Volume 3 mL | No longer on the market |
| Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe FID185704 | FID185704 / FID185704 | M71389122049663SAM1 | Total Volume 3 mL | No longer on the market |
| Hymovis® High Molecular Weight Viscoelastic Hyaluronan, 24mg/3ml syringe, 1 pack 89122-0496-01 | 89122-0496-01 / 89122-0496-01 | M713891220496010 | Total Volume 3 mL | On the market |
| HYMOVIS® ONE 32mg/4ml syringe 89122-0750-01 | 89122-0750-01 / 89122-0750-01 | M713891220750010 | Total Volume 3 mL | On the market |
| HYMOVIS® ONE Professional Sample, 32mg/4ml syringe FID07501 | FID07501 / FID07501 | M713FID075010 | Total Volume 3 mL | On the market |
Similar devices
Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).
- Synvisc Hylan G-F 20 by Sanofi Genzyme Corp.
- TRILURON by Fidia Farmaceutici S.p.A.
- Supartz by Seikagaku Corp.
- Gel-One by Seikagaku Corp.
- GenVisc 850 by Channel-Markers Medical, LLC
- Orthovisc High Molecular Weight Hyaluronan by Anika Therapeutics, Inc.
- Hyalgan Acid, Hyaluronic, Intraarticular by Fidia Farmaceutici S.p.A.
- Euflexxa (1% Sodium Hyaluronate) by Ferring Pharmaceuticals, Inc.
- Durolane by BIOVENTUS LLC
- Gel-Syn Acid, Hyaluronic, Intraarticular by Ibsa Institut Biochimique SA